Recent Accomplishments

  • Qool Therapeutics has raised an $8 million Series A-1 round for clinical product development and to prepare for first-in-human studies.

  • The Company recently signed a collaborative research and development agreement or CRADA to complete animal research with the US Army Institute of Surgical Research in order to evaluate the technology for several military applications.
  • In addition, the Company recently closed a convertible note seed round led by angelMD and Michael Dillingham, M.D., team doctor for the San Francisco Giants baseball team.
  • Qool Therapeutics Company won the prestigious 2014 Transcatheter Therapies (TCT) Innovation Competition for most innovative product.

Qool Therapeutics has raised an $8 million Series A-1 round for clinical product development and to prepare for first-in-human studies.

The Company recently signed a collaborative research and development agreement or CRADA to complete animal research with the US Army Institute of Surgical Research in order to evaluate the technology for several military applications.

In addition, the Company recently closed a convertible note seed round led by angelMD and Michael Dillingham, M.D., team doctor for the San Francisco Giants baseball team.

Qool Therapeutics Company won the prestigious 2014 Transcatheter Therapies (TCT) Innovation Competition for most innovative product.